No.10-23

May 24, 2010
Eisai Co., Ltd.

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PIPELINE, PORTFOLIO AT ASCO ANNUAL MEETING

HIGHLIGHTS INCLUDE NEW PHASE III DATA ON INVESTIGATIONAL ANTICANCER AGENT ERIBULIN IN LOCALLY RECURRENT OR METASTATIC BREAST CANCER

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that fifteen abstracts highlighting the latest results from studies with its pipeline and portfolio products on metastatic breast cancer, ovarian cancer, non-small cell lung cancer, metastatic brain cancer, T-cell lymphoma and other cancers have been accepted for presentation during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, United States from June 4 to June 8, 2010.

Among the studies to be presented is an oral presentation of new data from a global phase III study (EMBRACE: **E**isai **M**etastatic **Br**east Cancer Study **A**ssessing Physician's **C**hoice Versus **E**7389) of the Company's investigational anticancer agent eribulin mesylate (generic name, "eribulin"). The EMBRACE Study is an open-label, randomized, parallel two-arm, multi-center study of eribulin versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with at least two chemotherapy regimens including an anthracycline and a taxane.

Eisai has long positioned integrative oncology as a therapeutic area of focus and has continued to prioritize the allocation of resources to research and development in this area. The accepted studies collectively reflect the Company's oncology pipeline and product portfolio strategy as well as pre-clinical and clinical oncology research.

Eisai will continue its commitment to actively pursuing the global discovery, development and production of oncology therapies representative of its human health care (*hhc*) philosophy to increase benefits to patients and their families, thereby making further contributions to addressing the diversified needs of and increasing the benefits to patients and their families as well as healthcare providers.

■ The following fourteen abstracts on Eisai's pipeline and portfolio products are accepted for presentation at this year's ASCO meeting:

Product	Abstract Details	Location Details
Eribulin Mesylate (E7389) Abstract No: CRA1004	A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane *Oral presentation*	June 8, 2010 9:30 AM－12:30 AM Location: E Hall D1
Eribulin Mesylate (E7389) Abstract No: 1081	Efficacy and safety of eribulin in Japanese patients with advanced breast cancer *Poster session*	June 5, 2010 2:00 PM－6:00 PM Location: S Hall A2

(Continued on next page)

Product	Abstract Details	Location Details
Eribulin Mesylate (E7389) Abstract No: 2589	Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors *Poster session*	June 7, 2010 8:00 AM－12:00 PM Location: S Hall A2
Eribulin Mesylate (E7389) Abstract No: 2582	Eribulin mesylate pharmacokinetics in patients with hepatic impairment *Poster session*	June 7, 2010 8:00 AM－12:00 PM Location: S Hall A2
Farletuzumab (MORAb-003) Abstract No: 5001	Efficacy and safety of farletuzamab, a humanized monocolonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study *Oral presentation*	June 7, 2010 9:45 AM－11:15 AM Location: E Arie Crown Theatre
Farletuzumab (MORAb-003) Abstract No: TPS255	A randomized, double blind, placebo controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer *Poster session*	June 7, 2010 8:00 AM –12:00 PM Location: S Hall A2
E7820 Abstract No: 3537	Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC) *Poster Session*	June 6, 2010 2:00 PM-6:00 PM Location: S Hall A2
Ontak® (denileukin diftitox) Abstract No: 8045	Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial *Poster session discussion*	June 4, 2010 5:00 PM－6:00 PM Location: E354b
E7080 Abstract No: 2540	A Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors *Poster session*	June 7, 2010 8:00 AM－12:00 PM Location: S Hall A2
E6201 Abstract No: 2505	A Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors *Oral presentation*	June 6, 2010 8:00 AM－9:30 AM Location: E354a
Gliadel® Wafer Abstract No: 2066	A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one-to-three brain metastases: Preliminary results *Poster session*	June 6, 2010 8:00 AM－12:00 PM Location: S Hall A2
Dacogen® (decitabine) Abstract No: 6600	Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS) *Poster session*	June 5, 2010 8:00 AM－12:00 PM Location: S Hall A2
Dacogen® (decitabine) Abstract No: 6601	Hematologic outcomes of MDS treatment with hypomethylating agents in community practice *Poster session*	June 5, 2010 8:00 AM－12:00 PM Location: S Hall A2
Fragmin® (dalteparin sodium) Abstract No: 9115	A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer *Poster session*	June 7, 2010 1:00 PM－5:00 PM Location: S Hall A2
Aloxi® (palonosetron hydrochloride) Abstract No: 9127	Chemotherapy induced nausea and vomiting-associated hospital and ER visits in real-world practice: Palonosetron versus other 5-HT_3-RA anti-emetic regimens *Poster session*	June 7, 2010 1:00 PM－5:00 PM Location: S Hall A2

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120